Holen Sie sich die Stockscreener-App
13.41
1.67%
0.22
Schlusskurs vom Vortag:
$13.19
Offen:
$13.2
24-Stunden-Volumen:
2.25M
Relative Volume:
1.34
Marktkapitalisierung:
$4.22B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-19.71
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+3.47%
1M Leistung:
+10.19%
6M Leistung:
+62.35%
1J Leistung:
+61.37%
1-Tages-Spanne:
$13.09
$13.47
1-Wochen-Bereich:
$12.66
$13.47
52-Wochen-Spanne:
$6.685
$13.48
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.41 | 4.15B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Portfolio Recap: Can Amneal Pharmaceuticals Inc be the next market leader2025 Analyst Calls & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Amneal unveils new brand identity to reimagine access to medicine - MediaNews4U
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - Yahoo Finance
Trade Recap: Is Amneal Pharmaceuticals Inc a potential multi baggerPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug PostEarnings: Will Fastenal Company benefit from rate cutsRecession Risk & Trade Opportunity Analysis Reports - baoquankhu1.vn
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run - Yahoo Finance
Amneal unveils bold new brand to reimagine what’s possible in making medicine accessible for all - Pharmabiz.com
Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report - TipRanks
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance - TradingView — Track All Markets
Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s - BioWorld MedTech
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 - Insider Monkey
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Nasdaq Moves: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsWeekly Investment Recap & Precise Swing Trade Entry Alerts - Улправда
Will Amneal Pharmaceuticals Inc. stock recover faster than peersStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock deliver strong dividend growthCushioning Options Review & HOKA model picks for your routine - ulpravda.ru
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance - PharmiWeb.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum - Sahm
KeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.com - Investing.com Canada
KeifeRX announces research collaboration & option agreement with Amneal Pharmaceuticals - MarketScreener
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease - Business Wire
Can Amneal Pharmaceuticals Inc. stock continue upward trendJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - Улправда
Why Amneal Pharmaceuticals Inc. stock remains a top recommendationMarket Risk Summary & Breakout Confirmation Trade Signals - ulpravda.ru
Smart Money: Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Miss & AI Enhanced Market Trend Forecasts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Price Momentum & Growth Oriented Trading Recommendations - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock vulnerable to regulatory risksTrade Risk Summary & Weekly Market Pulse Alerts - ulpravda.ru
What is the fair value of Amneal Pharmaceuticals Inc. stock nowFinancial Sector Performance & Superior Trading Portfolio - ulpravda.ru
Can This Healthcare Stock Keep Going After a Nearly 70% Surge? - Barchart.com
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Unveiling a 10% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com - Investing.com Canada
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Allspring Global Investments Holdings LLC Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
How Recent Q3 Beats And FDA Wins Are Shaping The Amneal Pharmaceuticals (AMRX) Story - Yahoo Finance
Latest FDA Denosumab Decisions Offer Mixed Verdicts - Citeline News & Insights
Suboxone Market is Going to Booming Growth 2025 With Top Key - openPR.com
Amneal Launches Complex Generic Fluorometho-lone Ophthalmic Suspension - Specialty Pharmacy Continuum
Amneal Pharma-mAbxience gets USFDA approval for Boncresa, Oziltus - Medical Dialogues
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):